$PAVM
PAVmed Inc. Stock $pavm

$pavm Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224045258 Filed on November 14, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q4
Revenue		$1.000M	$1.049M
YoY Change		26.42%	836.61%
Cost Of Revenue		$1.381M	$1.611M
YoY Change		-22.37%	-0.43%
Gross Profit		-$381.0K	-$562.0K
YoY Change		-61.44%	-62.68%
Gross Profit Margin		-38.1%	-53.57%
Selling, General & Admin		$9.569M	$11.72M
YoY Change		-12.0%	-25.9%
% of Gross Profit
Research & Development		$1.542M	$3.595M
YoY Change		-51.22%	-46.13%
% of Gross Profit
Depreciation & Amortization			$722.0K
YoY Change			-0.55%
% of Gross Profit
Operating Expenses		$11.11M	$15.82M
YoY Change		-20.83%	-31.21%
Operating Profit		-$11.58M	-$16.38M
YoY Change		-25.44%	-33.14%
Interest Expense			-$275.0K
YoY Change			-213.17%
% of Operating Profit
Other Income/Expense, Net		$72.29M	$0.00
YoY Change		-1261.83%
Pretax Income		$60.71M	-$17.41M
YoY Change		-379.13%	-29.16%
Income Tax			$0.00
% Of Pretax Income
Net Earnings		$64.40M	-$15.91M
YoY Change		-464.43%	-22.54%
Net Earnings / Revenue		6439.9%	-1516.21%
Basic Earnings Per Share		$6.43
Diluted Earnings Per Share		$1.44	-$1.98
COMMON SHARES
Basic Shares Outstanding	11.07M shares	10.41M shares	120.8M shares
Diluted Shares Outstanding		44.48M shares

Balance Sheet

Concept	2024 Q3	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments		$22.31M
YoY Change		-47.81%
Cash & Equivalents	$765.0K	$19.64M
Short-Term Investments
Other Short-Term Assets		$1.848M
YoY Change		59.31%
Inventory	$6.000K	$278.0K
Prepaid Expenses
Receivables	$16.00K	$61.00K
Other Receivables		$0.00
Total Short-Term Assets	$2.130M	$24.50M
YoY Change	-93.44%	-44.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$216.0K	$1.783M
YoY Change	-88.13%	-27.25%
Goodwill
YoY Change
Intangibles	$0.00	$1.424M
YoY Change	-100.0%	-58.66%
Long-Term Investments	$25.51M
YoY Change
Other Assets	$75.00K	$1.147M
YoY Change	-93.46%	2.32%
Total Long-Term Assets	$28.42M	$8.621M
YoY Change	197.31%	-14.25%
TOTAL ASSETS
Total Short-Term Assets	$2.130M	$24.50M
Total Long-Term Assets	$28.42M	$8.621M
Total Assets	$30.55M	$33.12M
YoY Change	-27.3%	-38.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$465.0K	$1.786M
YoY Change	-78.52%	-33.95%
Accrued Expenses	$4.543M	$6.626M
YoY Change	-17.17%	78.84%
Deferred Revenue
YoY Change
Short-Term Debt		$44.20M
YoY Change		27.04%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$37.56M	$54.18M
YoY Change	-31.09%	31.5%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities		$2.960M
YoY Change		60.35%
Total Long-Term Liabilities		$2.960M
YoY Change		60.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$37.56M	$54.18M
Total Long-Term Liabilities		$2.960M
Total Liabilities	$39.94M	$57.14M
YoY Change	-30.96%	32.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$256.3M	-$294.4M
YoY Change	-7.98%	29.04%
Common Stock	$11.00K	$9.000K
YoY Change	-90.83%	-90.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.869M	-$53.83M
YoY Change
Total Liabilities & Shareholders Equity	$30.55M	$33.12M
YoY Change	-27.3%	-38.65%

Cashflow Statement

Concept	2024 Q3	2023 Q4
OPERATING ACTIVITIES
Net Income	$64.40M	-$15.91M
YoY Change	-464.43%	-22.54%
Depreciation, Depletion And Amortization		$722.0K
YoY Change		-0.55%
Cash From Operating Activities		-$11.88M
YoY Change		-29.41%
INVESTING ACTIVITIES
Capital Expenditures		$182.0K
YoY Change		-38.93%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change
Cash From Investing Activities		-$182.0K
YoY Change		-38.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		5.283M
YoY Change		6503.75%
NET CHANGE
Cash From Operating Activities		-11.88M
Cash From Investing Activities		-182.0K
Cash From Financing Activities		5.283M
Net Change In Cash		-6.775M
YoY Change		-60.24%
FREE CASH FLOW
Cash From Operating Activities		-$11.88M
Capital Expenditures		$182.0K
Free Cash Flow		-$12.06M
YoY Change		-29.57%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1516000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3161000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5125000	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-9387000	usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	765000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	278000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1343000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4520000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	24498000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	216000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1783000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2618000	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001624326
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37685
	dei	Entity Registrant Name EntityRegistrantName	PAVMED INC.
	dei	Entity Address Address Line2 EntityAddressAddressLine2	25th Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Local Phone Number LocalPhoneNumber	813-1828
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q3	us-gaap	Assets Current AssetsCurrent	2130000	usd
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	996000	usd
CY2024Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2920000	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6649000	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	82000	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1542000	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-11578000	usd
CY2024Q3	us-gaap	Interest Income Operating InterestIncomeOperating	70000	usd
CY2024Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	12000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33648000	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount		usd
	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount		usd
CY2023Q3	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss		usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss		usd
CY2024Q3	PAVM	Loss On Issue And Offering Cost Senior Secured Convertible Note LossOnIssueAndOfferingCostSeniorSecuredConvertibleNote		usd
CY2023Q3	PAVM	Loss On Issue And Offering Cost Senior Secured Convertible Note LossOnIssueAndOfferingCostSeniorSecuredConvertibleNote		usd
	PAVM	Loss On Issue And Offering Cost Senior Secured Convertible Note LossOnIssueAndOfferingCostSeniorSecuredConvertibleNote		usd
CY2024Q3	PAVM	Debt Modification Expense DebtModificationExpense		usd
CY2023Q3	PAVM	Debt Modification Expense DebtModificationExpense		usd
	PAVM	Debt Modification Expense DebtModificationExpense		usd
CY2024Q3	PAVM	Change In Fair Value Derivative Liability ChangeInFairValueDerivativeLiability		usd
	PAVM	Change In Fair Value Derivative Liability ChangeInFairValueDerivativeLiability		usd
CY2023Q3	PAVM	Management Fee Income ManagementFeeIncome		usd
	PAVM	Management Fee Income ManagementFeeIncome		usd
CY2024Q3	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets		usd
CY2023Q3	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets		usd
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets		usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q3	PAVM	Preferred Stock Dividends Attributable To Non Controlling Interests PreferredStockDividendsAttributableToNonControllingInterests		usd
CY2023Q3	PAVM	Preferred Stock Dividends Attributable To Non Controlling Interests PreferredStockDividendsAttributableToNonControllingInterests		usd
	PAVM	Preferred Stock Dividends Attributable To Non Controlling Interests PreferredStockDividendsAttributableToNonControllingInterests		usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend		usd
CY2024Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
CY2024Q3	PAVM	Stock Issued During The Periof Of New Issue Impact Of Subsidiary Equity Transactions StockIssuedDuringThePeriofOfNewIssueImpactOfSubsidiaryEquityTransactions		usd
	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend		usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
	PAVM	Stock Issued During The Periof Of New Issue Impact Of Subsidiary Equity Transactions StockIssuedDuringThePeriofOfNewIssueImpactOfSubsidiaryEquityTransactions		usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend		usd
CY2023Q3	PAVM	Stock Issued During The Periof Of New Issue Impact Of Subsidiary Equity Transactions StockIssuedDuringThePeriofOfNewIssueImpactOfSubsidiaryEquityTransactions		usd
	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend		usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
	PAVM	Stock Issued During The Periof Of New Issue Impact Of Subsidiary Equity Transactions StockIssuedDuringThePeriofOfNewIssueImpactOfSubsidiaryEquityTransactions		usd
	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued		usd
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets		usd
	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount		usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss		usd
	PAVM	Issuance Of Common Stock Installment Settlement Payment IssuanceOfCommonStockInstallmentSettlementPayment		usd
	PAVM	Loss On Issue And Offering Costs Senior Secured Convertible Note LossOnIssueAndOfferingCostsSeniorSecuredConvertibleNote		usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	PAVM	Decrease In Cash Due To Deconsolidation Of Subsidiary DecreaseInCashDueToDeconsolidationOfSubsidiary		usd
	PAVM	Proceeds From Sale Of Property Held For Sales ProceedsFromSaleOfPropertyHeldForSales		usd
	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale		usd
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt		usd
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt		usd
	PAVM	Proceeds Subsidiary Common Stock Committed Equity Facility And Atthemarket Facility ProceedsSubsidiaryCommonStockCommittedEquityFacilityAndAtthemarketFacility		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet		usd
CY2024Q3	PAVM	Deemed Dividend On Subsidiary Preferred Stock Attributable To Noncontrolling Interests DeemedDividendOnSubsidiaryPreferredStockAttributableToNoncontrollingInterests		usd
CY2023Q3	PAVM	Deemed Dividend On Subsidiary Preferred Stock Attributable To Noncontrolling Interests DeemedDividendOnSubsidiaryPreferredStockAttributableToNoncontrollingInterests		usd
	PAVM	Deemed Dividend On Subsidiary Preferred Stock Attributable To Noncontrolling Interests DeemedDividendOnSubsidiaryPreferredStockAttributableToNoncontrollingInterests		usd
CY2023Q3	PAVM	Fair Value Adjustment For Diluted Eps Calculation FairValueAdjustmentForDilutedEpsCalculation		usd
	PAVM	Fair Value Adjustment For Diluted Eps Calculation FairValueAdjustmentForDilutedEpsCalculation		usd
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1214177
	dei	Entity Address Address Line1 EntityAddressAddressLine1	360 Madison Avenue
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10017
	dei	City Area Code CityAreaCode	(917)
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10985841	shares
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11068566	shares
	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.001
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19639000	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	61000	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	6000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4267000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1424000	usd
CY2024Q3	us-gaap	Equity Method Investments EquityMethodInvestments	25511000	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	75000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1147000	usd
CY2024Q3	us-gaap	Assets Assets	30550000	usd
CY2023Q4	us-gaap	Assets Assets	33119000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	465000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1786000	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4543000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6626000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	499000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1565000	usd
CY2024Q3	us-gaap	Secured Debt Current SecuredDebtCurrent	32050000	usd
CY2023Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	44200000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	37557000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	54177000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2380000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2960000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	39937000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	57137000	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue	3232000	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	2993000	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10660394	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8578505	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	11000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	9000	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	248200000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	237600000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-256312000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-294433000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-4869000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-53831000	usd
CY2024Q3	us-gaap	Minority Interest MinorityInterest	-4518000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	29813000	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-9387000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-24018000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30550000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33119000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	791000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2985000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1403000	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	1381000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	1779000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	4792000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	4809000	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4016000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	11472000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	12893000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6858000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20337000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23916000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	505000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	559000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10681000	usd
CY2024Q3	us-gaap	Costs And Expenses CostsAndExpenses	12574000	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	16319000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	42285000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	53815000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-15528000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-39300000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-52412000	usd
CY2023Q3	us-gaap	Interest Income Operating InterestIncomeOperating	124000	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	252000	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	408000	usd
CY2023Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	159000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	38000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	570000	usd
CY2024Q3	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	72287000	usd
	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	72287000	usd
CY2024Q3	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	407000	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	407000	usd
CY2024Q3	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	-240000	usd
CY2023Q3	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	4392000	usd
	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	2488000	usd
	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	5772000	usd
	PAVM	Loss On Issue And Offering Cost Senior Secured Convertible Note LossOnIssueAndOfferingCostSeniorSecuredConvertibleNote	1186000	usd
CY2024Q3	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-1403000	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-1764000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-2535000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-3032000	usd
	PAVM	Debt Modification Expense DebtModificationExpense	-2000000	usd
CY2023Q3	PAVM	Change In Fair Value Derivative Liability ChangeInFairValueDerivativeLiability	31000	usd
	PAVM	Change In Fair Value Derivative Liability ChangeInFairValueDerivativeLiability	291000	usd
CY2024Q3	PAVM	Management Fee Income ManagementFeeIncome	700000	usd
	PAVM	Management Fee Income ManagementFeeIncome	700000	usd
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	1000000	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	72289000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6222000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	66585000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9443000	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	60711000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21750000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	27285000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-61855000	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	60711000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-21750000	usd
	us-gaap	Profit Loss ProfitLoss	27285000	usd
	us-gaap	Profit Loss ProfitLoss	-61855000	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3688000	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4079000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-11075000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-11716000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	64399000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-17671000	usd
	us-gaap	Net Income Loss NetIncomeLoss	38360000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-50139000	usd
CY2024Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	83000	usd
CY2023Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	77000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	244000	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	226000	usd
	PAVM	Preferred Stock Dividends Attributable To Non Controlling Interests PreferredStockDividendsAttributableToNonControllingInterests	7496000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	64316000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17748000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	30620000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-50365000	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	6.43
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.38
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.30
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.23
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.44
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.38
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.79
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.23
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10005379	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7462751	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9286999	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6967764	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44475638	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7462751	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43069449	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6967764	shares
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-18642000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	284000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	908000	usd
CY2024Q3	PAVM	Stock Issued During Period Value Conversions Subsidiary Common Stock Senior Secured Convertible Note StockIssuedDuringPeriodValueConversionsSubsidiaryCommonStockSeniorSecuredConvertibleNote	1260000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	150000	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	696000	usd
CY2024Q3	PAVM	Adjustments To Additional Paid In Capital Share Based Compensation Subsidiary AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationSubsidiary	1235000	usd
CY2024Q3	PAVM	Adjustments To Additional Paid In Capital Transfer Of Intellectual Property AdjustmentsToAdditionalPaidInCapitalTransferOfIntellectualProperty	350000	usd
CY2024Q3	PAVM	Adjustments To Additional Paid In Capital Deconsolidation Of Subsidiary AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary	-56339000	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	60711000	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-9387000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-24018000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	977000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2021000	usd
	PAVM	Stock Issued During Period Value Conversions Subsidiary Common Stock Senior Secured Convertible Note StockIssuedDuringPeriodValueConversionsSubsidiaryCommonStockSeniorSecuredConvertibleNote	3801000	usd
	PAVM	Adjustment To Additional Paid In Capital Issue Common Stock Of Subsidiary AdjustmentToAdditionalPaidInCapitalIssueCommonStockOfSubsidiary	4000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	62000	usd
	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	353000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	601000	usd
	PAVM	Issuance Subsidiary Preferred Stock Series A One IssuanceSubsidiaryPreferredStockSeriesAOne	5670000	usd
	PAVM	Issuance Of Exchange Subsidiary Preferred Stock Series And Series A One IssuanceOfExchangeSubsidiaryPreferredStockSeriesAndSeriesAOne	-24294000	usd
	PAVM	Issuance Of Exchange Sale Subsidiary Preferred Stock Series B And Series B One IssuanceOfExchangeSaleSubsidiaryPreferredStockSeriesBAndSeriesBOne	31790000	usd
	PAVM	Issuance Of Exchange Subsidiary Preferred Stock Series B And Series B One IssuanceOfExchangeSubsidiaryPreferredStockSeriesBAndSeriesBOne	24129000	usd
	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	7496000	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	2228000	usd
	PAVM	Stock Issued During Period Value Stockbased Compensation Subsidiary StockIssuedDuringPeriodValueStockbasedCompensationSubsidiary	3489000	usd
	PAVM	Adjustments To Additional Paid In Capital Transfer Of Intellectual Property AdjustmentsToAdditionalPaidInCapitalTransferOfIntellectualProperty	350000	usd
	PAVM	Adjustments To Additional Paid In Capital Deconsolidation Of Subsidiary AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary	-56339000	usd
	us-gaap	Profit Loss ProfitLoss	27285000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-830000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3989000	usd
CY2023Q3	PAVM	Stock Issued During Period Value Conversions Subsidiary Common Stock Senior Secured Convertible Note StockIssuedDuringPeriodValueConversionsSubsidiaryCommonStockSeniorSecuredConvertibleNote	167000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	76000	usd
CY2023Q3	PAVM	Purchase Majorityowned Subsidiary Common Stock Employee Stock Purchase Plan PurchaseMajorityownedSubsidiaryCommonStockEmployeeStockPurchasePlan	275000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	978000	usd
CY2023Q3	PAVM	Stock Issued During Period Value Stockbased Compensation Subsidiary StockIssuedDuringPeriodValueStockbasedCompensationSubsidiary	1267000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-21750000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-15828000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10934000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10934000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1166000	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	8411000	usd
	PAVM	Stock Issued During Period Value Conversions Subsidiary Common Stock Senior Secured Convertible Note StockIssuedDuringPeriodValueConversionsSubsidiaryCommonStockSeniorSecuredConvertibleNote	167000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	258000	usd
	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	551000	usd
	PAVM	Issuance Subsidiary Common Stock Committed Equity Facility Net Of Financing Charges IssuanceSubsidiaryCommonStockCommittedEquityFacilityNetOfFinancingCharges	284000	usd
	PAVM	Stock Issued During Period Value Issuance Subsidiary Common Stock Settlement Apardx Installment Payment StockIssuedDuringPeriodValueIssuanceSubsidiaryCommonStockSettlementApardxInstallmentPayment	713000	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	747000	usd
	PAVM	Issuance Subsidiary Preferred Stock Series A IssuanceSubsidiaryPreferredStockSeriesA	13625000	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	3266000	usd
	PAVM	Stock Issued During Period Value Stockbased Compensation Subsidiary StockIssuedDuringPeriodValueStockbasedCompensationSubsidiary	5905000	usd
	us-gaap	Profit Loss ProfitLoss	-61855000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-15828000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-15828000	usd
	us-gaap	Profit Loss ProfitLoss	27285000	usd
	us-gaap	Profit Loss ProfitLoss	-61855000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1129000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2207000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5716000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9171000	usd
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	1000000	usd
	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	72287000	usd
	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	407000	usd
	PAVM	Issuance Of Common Stock Installment Settlement Payment IssuanceOfCommonStockInstallmentSettlementPayment	713000	usd
	PAVM	Amortization Of Common Stock Payment For Vendor Service Agreement AmortizationOfCommonStockPaymentForVendorServiceAgreement	448000	usd
	PAVM	Amortization Of Common Stock Payment For Vendor Service Agreement AmortizationOfCommonStockPaymentForVendorServiceAgreement	625000	usd
	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	2488000	usd
	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	5772000	usd
	PAVM	Loss On Issue And Offering Costs Senior Secured Convertible Note LossOnIssueAndOfferingCostsSeniorSecuredConvertibleNote	1111000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-2535000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-3032000	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-291000	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	8000	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	304000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-45000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	18000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-579000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	1757000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-249000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-538000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-938000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1780000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-40162000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	51000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	59000	usd
	PAVM	Decrease In Cash Due To Deconsolidation Of Subsidiary DecreaseInCashDueToDeconsolidationOfSubsidiary	16479000	usd
	PAVM	Proceeds From Sale Of Property Held For Sales ProceedsFromSaleOfPropertyHeldForSales	350000	usd
	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	1000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16180000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	941000	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	29798000	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	13625000	usd
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	10000000	usd
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	531000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1268000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1166000	usd
	PAVM	Proceeds Subsidiary Common Stock Committed Equity Facility And Atthemarket Facility ProceedsSubsidiaryCommonStockCommittedEquityFacilityAndAtthemarketFacility	284000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	62000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	259000	usd
	PAVM	Proceeds Subsidiary Common Stock Employee Stock Purchase Plan ProceedsSubsidiaryCommonStockEmployeeStockPurchasePlan	353000	usd
	PAVM	Proceeds Subsidiary Common Stock Employee Stock Purchase Plan ProceedsSubsidiaryCommonStockEmployeeStockPurchasePlan	551000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	30954000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25885000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-18874000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-13336000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	19639000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39744000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	765000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	26408000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_806_eus-gaap--NatureOfOperations_z24yawsHTudh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 — <span id="xdx_82F_zWHj3RUh3Un2">The Company</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Description of the Business</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PAVmed is structured to be a multi-product life sciences company organized to advance a pipeline of innovative healthcare technologies. Led by a team of highly skilled personnel with a track record of bringing innovative products to market, PAVmed is focused on innovating, developing, acquiring, and commercializing novel products that target unmet medical needs with large addressable market opportunities. Leveraging our corporate structure—a parent company that will establish distinct subsidiaries for each financed asset—we have the flexibility to raise capital at the PAVmed level to fund product development, or to structure financing directly into each subsidiary in a manner tailored to the applicable product, the latter of which is our current strategy given prevailing market conditions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our current focus is multi-fold. We continue to pursue commercial expansion and execution of EsoGuard, which is the flagship product of our subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”). In addition, through a separate majority-owned subsidiary, Veris Health (“Veris”), we are focused in the immediate term on entering into strategic partnership opportunities with leading academic oncology systems to expand access to the Veris Platform, while concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Platform. In terms of other existing products and technologies, we have adopted an incubator-type platform where we are looking to obtain financing on a product-by-product basis as necessary to advance each asset to a meaningful inflection point along its path to commercialization. Finally, as resources permit, we will continue to explore external innovations that fulfill our project selection criteria without limiting ourselves to any target sector, specialty or condition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	us-gaap	Revenues Revenues	1000000.0	usd
	us-gaap	Revenues Revenues	3000000.0	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	30600000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33600000	usd
CY2024Q3	PAVM	Working Capital WorkingCapital	-35400000	usd
CY2024Q3	us-gaap	Secured Debt Current SecuredDebtCurrent	32100000	usd
CY2024Q3	us-gaap	Cash Cash	800000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_ziWnTLPZOw4b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and the determination of corresponding carrying value reserve, if any, and liabilities and the disclosure of contingent losses, as of the date of the unaudited condensed consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates in these unaudited condensed consolidated financial statements include those related to the estimated fair value of debt obligations, stock-based equity awards, intangible assets and common stock purchase warrants. Other significant estimates include the estimated incremental borrowing rate, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. Additionally, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates and assumptions. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3 — Summary of Significant Accounting Policies</b> - continued</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2024Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	996000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2985000	usd
CY2023Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	791000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1403000	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	1381000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	4792000	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	1779000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	4809000	usd
CY2024Q3	PAVM	Prepaid Service Providers And Suppliers PrepaidServiceProvidersAndSuppliers	181000	usd
CY2023Q4	PAVM	Prepaid Service Providers And Suppliers PrepaidServiceProvidersAndSuppliers	739000	usd
CY2024Q3	us-gaap	Prepaid Insurance PrepaidInsurance	420000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	848000	usd
CY2024Q3	us-gaap	Security Deposit SecurityDeposit	480000	usd
CY2023Q4	us-gaap	Security Deposit SecurityDeposit	2672000	usd
CY2024Q3	PAVM	Veris Box Supplies VerisBoxSupplies	262000	usd
CY2023Q4	PAVM	Veris Box Supplies VerisBoxSupplies	261000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1343000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4520000	usd
CY2024Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	174000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	708000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	724000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	594000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	471000	usd
CY2024Q3	PAVM	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	848000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3519000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	640000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2879000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1407000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1080000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2728000	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y3M
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y8M4D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07875	pure
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07875	pure
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2618000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4267000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	2879000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4525000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	499000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1565000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2380000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2960000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	70000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5375000	usd
CY2024Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	70000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3951000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1424000	usd
CY2024Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	82000	usd
CY2023Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	505000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	559000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1516000	usd
CY2024Q3	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	0	usd
CY2024Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	25511000	usd
CY2024Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	32050000	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	44200000	usd
CY2024Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	25229000	usd
CY2024Q3	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	32050000	usd
CY2023Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	37683000	usd
CY2023Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	44200000	usd
CY2024Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	44000000	usd
CY2024Q3	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	1252000	usd
CY2024Q3	us-gaap	Debt Instrument Repaid Principal DebtInstrumentRepaidPrincipal	190000	usd
CY2024Q3	PAVM	Deconsolidation Fair Value Of Debt DeconsolidationFairValueOfDebt	-10268000	usd
CY2024Q3	PAVM	Debt Instruments Fair Value DebtInstrumentsFairValue	-240000	usd
CY2024Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	32050000	usd
CY2024Q3	PAVM	Other Income Expense Change In Fair Value OtherIncomeExpenseChangeInFairValue	-240000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	44200000	usd
	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	3440000	usd
	us-gaap	Debt Instrument Repaid Principal DebtInstrumentRepaidPrincipal	930000	usd
	PAVM	Deconsolidation Fair Value Of Debt DeconsolidationFairValueOfDebt	-10268000	usd
	PAVM	Debt Instruments Fair Value DebtInstrumentsFairValue	2488000	usd
CY2024Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	32050000	usd
	PAVM	Other Income Expense Change In Fair Value OtherIncomeExpenseChangeInFairValue	2488000	usd
CY2023Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	42990000	usd
CY2023Q3	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	2251000	usd
CY2023Q3	us-gaap	Debt Instrument Repaid Principal DebtInstrumentRepaidPrincipal	141000	usd
CY2023Q3	PAVM	Debt Instruments Fair Value DebtInstrumentsFairValue	4392000	usd
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	44990000	usd
CY2023Q3	PAVM	Other Income Expense Change In Fair Value OtherIncomeExpenseChangeInFairValue	4392000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	33650000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	33650000	usd
	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	11111000	usd
	PAVM	Fair Value Adjustment Issue Date FairValueAdjustmentIssueDate	789000	usd
	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	5194000	usd
	us-gaap	Debt Instrument Repaid Principal DebtInstrumentRepaidPrincipal	349000	usd
	PAVM	Debt Instruments Fair Value DebtInstrumentsFairValue	4983000	usd
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	44990000	usd
CY2023Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	44990000	usd
	PAVM	Other Income Expense Change In Fair Value OtherIncomeExpenseChangeInFairValue	5772000	usd
CY2024Q3	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-1403000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-2535000	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-1764000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-3032000	usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	66720	shares
CY2024Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1931000	usd
CY2023Q3	us-gaap	Share Based Compensation ShareBasedCompensation	2245000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5716000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9171000	usd
CY2023Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-15
CY2023Q4	PAVM	Stock Issused And Outstanding Description StockIssusedAndOutstandingDescription	every 15 shares of the Company’s common stock that were issued and outstanding were automatically combined into one issued and outstanding share, without any change in par value of such shares.
CY2024Q1	us-gaap	Debt Instrument Fee DebtInstrumentFee	On March 7, 2024, the Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that, for the prior 30 consecutive business days (through March 6, 2024), the market value of the Company’s listed securities had been below the minimum of $35 million required for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). The Company was provided 180 calendar days, or until September 3, 2024, to regain compliance with the rule. The Company did not regain compliance with the rule during the allotted time period. Accordingly, on September 10, 2024, the Company received a staff determination letter from the Nasdaq Listing Qualifications Department, stating that unless the Company timely requested a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal the staff determination, the Company’s securities would be subject to suspension and delisting. The Company timely requested a hearing before the Panel, which was held on October 29, 2024.
	PAVM	Stock Issued During Period Share Atm Facilities StockIssuedDuringPeriodShareATMFacilities	627302	shares
	PAVM	Stock Issued During Period Value Atm Facilities StockIssuedDuringPeriodValueATMFacilities	977000	usd
	PAVM	Payments For Commissions Percentage PaymentsForCommissionsPercentage	0.03	pure
CY2024Q1	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.52
CY2024Q1	us-gaap	Share Price SharePrice	0.37709668
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	23.48
CY2023Q4	us-gaap	Minority Interest MinorityInterest	29813000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-11075000	usd
	PAVM	Impact Of Subsidiary Equity Transactions ImpactOfSubsidiaryEquityTransactions	-4414000	usd
	PAVM	Lucid Diagnostics Proceeds From Issuance Of Preferred Stock Series A One LucidDiagnosticsProceedsFromIssuanceOfPreferredStockSeriesAOne	5670000	usd
	PAVM	Lucid Diagnostics Exchange Of Preferred Stock Series And Series A One LucidDiagnosticsExchangeOfPreferredStockSeriesAndSeriesAOne	-24294000	usd
	PAVM	Lucid Diagnostics Issuance Through Exchange Series B And Series B One LucidDiagnosticsIssuanceThroughExchangeSeriesBAndSeriesBOne	31790000	usd
	PAVM	Lucid Diagnostics Issuance Through Sale Series B And Series B One LucidDiagnosticsIssuanceThroughSaleSeriesBAndSeriesBOne	24129000	usd
	PAVM	Lucid Diagnostics Deemed Dividend On Preferred Stock LucidDiagnosticsDeemedDividendOnPreferredStock	-7496000	usd
	PAVM	Lucid Diagnostics Issuance Of Common Stock For Settlement Of Vendor Service Agreement LucidDiagnosticsIssuanceOfCommonStockForSettlementOfVendorServiceAgreement	401000	usd
	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValue	4000	usd
	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value Four AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueFour	353000	usd
	PAVM	Issue Common Stock Upon Partial Conversions Of Majority Owned Subsidiary Common Senior Secured Convertible Note IssueCommonStockUponPartialConversionsOfMajorityOwnedSubsidiaryCommonSeniorSecuredConvertibleNote	3801000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2771000	usd
	PAVM	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Values AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValues	368000	usd
	PAVM	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Deconsolidation Of Lucid AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteDeconsolidationOfLucid	-56339000	usd
CY2024Q3	us-gaap	Minority Interest MinorityInterest	-4518000	usd
CY2024Q1	PAVM	Fair Value Of Series B Preferred Stock Issued FairValueOfSeriesBPreferredStockIssued	31790000	usd
CY2024Q1	PAVM	Fair Value Of Series B Preferred Stock Issued Shares FairValueOfSeriesBPreferredStockIssuedShares	31790	shares
CY2024Q1	PAVM	Fair Value Of Series B Preferred Stock Issued FairValueOfSeriesBPreferredStockIssued	31790000	usd
CY2024Q1	PAVM	Less Carrying Value Related To Series And Series A1 Preferred Stock Exchanged For Series B Preferred Stock Shares LessCarryingValueRelatedToSeriesAndSeriesA1PreferredStockExchangedForSeriesBPreferredStockShares	24295	shares
CY2024Q1	PAVM	Less Carrying Value Related To Series And Series A1 Preferred Stock Exchanged For Series B Preferred Stock LessCarryingValueRelatedToSeriesAndSeriesA1PreferredStockExchangedForSeriesBPreferredStock	24294000	usd
CY2024Q1	PAVM	Deemed Dividend Charged To Accumulated Deficit DeemedDividendChargedToAccumulatedDeficit	7496000	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	60711000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-21750000	usd
	us-gaap	Profit Loss ProfitLoss	27285000	usd
	us-gaap	Profit Loss ProfitLoss	-61855000	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3688000	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4079000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-11075000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-11716000	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	64399000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-17671000	usd
	us-gaap	Net Income Loss NetIncomeLoss	38360000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-50139000	usd
CY2024Q3	PAVM	Preferred Stock Dividends Series B PreferredStockDividendsSeriesB	-83000	usd
CY2023Q3	PAVM	Preferred Stock Dividends Series B PreferredStockDividendsSeriesB	-77000	usd
	PAVM	Preferred Stock Dividends Series B PreferredStockDividendsSeriesB	-244000	usd
	PAVM	Preferred Stock Dividends Series B PreferredStockDividendsSeriesB	-226000	usd
	PAVM	Deemed Dividend On Subsidiary Preferred Stock Attributable To Noncontrolling Interests DeemedDividendOnSubsidiaryPreferredStockAttributableToNoncontrollingInterests	-7496000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	64316000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17748000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	30620000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-50365000	usd
CY2024Q3	PAVM	Fair Value Adjustment For Diluted Eps Calculation FairValueAdjustmentForDilutedEpsCalculation	-240000	usd
	PAVM	Fair Value Adjustment For Diluted Eps Calculation FairValueAdjustmentForDilutedEpsCalculation	3378000	usd
CY2024Q3	PAVM	Net Income Loss Available To Common Stockholders NetIncomeLossAvailableToCommonStockholders	64076000	usd
CY2023Q3	PAVM	Net Income Loss Available To Common Stockholders NetIncomeLossAvailableToCommonStockholders	-17748000	usd
	PAVM	Net Income Loss Available To Common Stockholders NetIncomeLossAvailableToCommonStockholders	33998000	usd
	PAVM	Net Income Loss Available To Common Stockholders NetIncomeLossAvailableToCommonStockholders	-50365000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10005379	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7462751	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9286999	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6967764	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44475638	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7462751	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43069449	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6967764	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	6.43
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.38
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.30
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.23
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.44
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.38
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.79
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.23
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2028937	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2090297	shares
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-045258-index-headers.html	Edgar Link	pending
0001493152-24-045258-index.html	Edgar Link	pending
0001493152-24-045258.txt	Edgar Link	pending
0001493152-24-045258-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pavm-20240930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
pavm-20240930_def.xml	Edgar Link	unprocessable
pavm-20240930_lab.xml	Edgar Link	unprocessable
pavm-20240930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pavm-20240930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PAVM
PAVmed Inc. Stock $pavm

2024 Q4 Form 10-Q Financial Statement

#000149315224045258 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PAVM PAVmed Inc. Stock $pavm

2024 Q4 Form 10-Q Financial Statement

#000149315224045258 Filed on November 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PAVM
PAVmed Inc. Stock $pavm